About Cerus
Cerus is a publicly listed company based in Concord (United States) founded in 1991. It operates as a provider of pathogen inactivation technology for blood center or hospital blood bank. The company has 281 employees. Cerus offers products and services including INTERCEPT Blood System for Platelets and Plasma, INTERCEPT Blood System for Cryoprecipitation, and INTERCEPT Red Blood Cell System. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Therapeutics. Its legal entity is Cerus Corporation. Its competitors include Aethlon Medical, Amferia, Ondine Biomedical, 3Oe Scientific and Larada Sciences and 3 more; 4 of its 8 listed competitors have raised funding.
Company details
Cerus was founded in 1991 and is headquartered in Concord, United States. Operations focus on the healthcare sector, where pathogen inactivation systems are developed for blood banks and centers. The INTERCEPT system is utilized to process platelets and plasma from whole blood and apheresis sources. Amotosalen-based technology is employed to inactivate viruses, bacteria, and parasites, thereby addressing transfusion-related infection risks.
- Annual Revenue$206.13 M (USD)14.35as on Dec 31, 2025
- Net Profit-$15.63 M (USD)25.29as on Dec 31, 2025
- EBITDA-$34.35 M (USD)-3.22as on Dec 31, 2025
- InvestorsNCBI
& 2 more
- Employee Count281
Products & Services of Cerus
Cerus offers a comprehensive portfolio of products and services, including INTERCEPT Blood System for Platelets and Plasma, INTERCEPT Blood System for Cryoprecipitation, and INTERCEPT Red Blood Cell System.
Reduces pathogens in blood platelets and plasma for safe transfusions
Produces pathogen-reduced fibrinogen complex for bleeding control
In development to reduce pathogens in red blood cells
Funding Insights of Cerus
- Total Rounds 7
- First Round $78M
(May 2001)
- Investors Count 3
All 7 funding rounds of Cerus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | – | Grant | – | – | |
| Apr 2019 | $75M | Debt – Conventional | – | – | |
| Aug 2011 | $2.1M | Grant | – | – | |
| Sep 2010 | $1.4M | Grant | – | – | |
| Feb 2009 | $2.55M | Grant | – | – | |
| Jul 2008 | $2.55M | Grant | – | – | |
| May 2001 | $78M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Cerus
Cerus has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NCBI, MidCap Financial and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Provider of biomedical and genomic information access | 1988 | ncbi.nlm.nih.gov | Bethesda, United States | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States |
Investor details for Cerus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cerus
136 people are tracked at Cerus (69 in leadership, 8 in board & advisors, 59 in team); the tracked headcount is 281.
| Name | Role | Group |
|---|---|---|
Kevin D. Green | VP & CFO | Leadership |
Richard J. Benjamin | Chief Medical Officer | Leadership |
Nina Mufti | VP, Development | Leadership |
Lori L. Roll | VP, Administration & Corporate Secretary | Leadership |
Robert Wójcicki | Sales Director Distributor Markets Eemea | Leadership |
Spontaneous Russell | Associate Director, Product Management | Leadership |
Leslie Hallock | Senior Director Regulatory Affairs | Leadership |
Msc. Seth Donrovich | Associate Director, Marketing | Leadership |
Scott Buker | Vice President National Accounts | Leadership |
Houston Nguyen (Buddy) | Director Of Hospital Engagement And Education | Leadership |
Vijay Pasapula | Sr Director, Head Of Statistical Programming | Leadership |
William M. Greenman | President, CEO & Board Member | Leadership |
Vivek K. Jayaraman | Chief Operating Officer | Leadership |
Erin Kipperman | Regulatory Affairs Director | Leadership |
Monique Ono | Executive Assistant To The Chief Executive Officer And Chief Financial Officer | Leadership |
Jason Moran | Regional Business Director | Leadership |
Jay Dobbs | Regional Business Director - Hospitals | Leadership |
Molly McCarty | Strategic Accounts Director, Blood Centers | Leadership |
Christina Johansson | Associate Director, Outsourced Operations | Leadership |
Nour Ben Ezzeddine | Quality Assurance Director International | Leadership |
116 more people are available in the full profile.
Complete people profiles for Cerus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cerus
Cerus is a publicly listed company on the NASDAQ with ticker symbol CERS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jan 1997
- Listed onNASDAQ: CERS
- Listed entityCerus Corporation
- Exchange sectorHealth technology
- ISINUS1570851014
- Share price$2.26 · 2026-10-13
- Market capitalisation$455.4M
- EPS (diluted, trailing year)$-0.03
- Volume (last session)2,293,133
Financials of Cerus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $206.1M | -$15.6M | -$34.4M |
| 2024 | $180.3M | -$20.9M | -$33.3M |
| 2023 | $156.4M | -$37.5M | -$54.4M |
| 2022 | $162.1M | -$42.8M | -$55.8M |
| 2021 | $130.9M | -$54.4M | -$73.0M |
Detailed financial statements for Cerus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cerus
4 dated milestones of Cerus across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Cerus is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $78.0M.
- Funding Latest funding round, Grant,.
Competitors of Cerus
Cerus has 8 listed competitors in our database, 4 of them funded. They include Aethlon Medical, Amferia, Ondine Biomedical, 3Oe Scientific and Larada Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aethlonmedical.com | 1999 | San Diego, United States | – | 14 | Hemopurification devices are developed to eliminate viruses and exosomes. | |
| amferia.com | 2018 | Gothenburg, Sweden | $3.45M | – | Anti-infective technology is developed using selective anti-bacterial polymers. | |
| ondinebio.com | 1999 | Vancouver, Canada | – | 49 | Anti-infective therapies are developed via light-activated Photodisinfection technology. | |
| 3oescientific.com | 2010 | Carmel, United States | $3.71M | – | Provider of smart solutions to manage pathogen infections | |
| laradasciences.com | 2006 | Salt Lake, United States | $2.63M | – | Head lice are removed by a network of certified professionals. | |
| pathex.co | 2016 | Nashville, United States | $5M | – | Developing blood-cleansing device to remove pathogens from circulating blood | |
| zappkit.com | 2007 | Hafnarfjordur, Iceland | – | – | Provides frequency therapy through mobile app and hardware for user health support. | |
| tcubeit.com | 2019 | Sejong, South Korea | – | – | T cell-based immuno-therapeutics for cancer and infectious diseases are developed. |
Detailed competitors of Cerus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cerus
The website of Cerus (cerus.com) receives about 8.8K visits a month.
- Monthly visits8.8K
▲ 80.6% vs previous month
Websites whose visitors overlap most with Cerus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| machaondiagnostics.com | 100% | – | #2,768,798 | View details | |
| cytokinetics.com | 60% | 25.3K | #1,072,700 | View details |
Top companies in Infectious Diseases
10 companies that operate in the same segment as Cerus (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cerus
Complete news archive for Cerus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerus
Cerus was founded in 1991 and raised its 1st funding round 10 years after it was founded.
Cerus is headquartered in Concord, United States. It is registered at Concord, New Hampshire, United States.
Cerus has 281 employees.
Annual revenue of Cerus is $206.13M as on Dec 31, 2025.
Cerus was founded in 1991 and is headquartered in Concord, United States. Operations focus on the healthcare sector, where pathogen inactivation systems are developed for blood banks and centers. The INTERCEPT system is utilized to process platelets and plasma from whole blood and apheresis sources. Amotosalen-based technology is employed to inactivate viruses, bacteria, and parasites, thereby addressing transfusion-related infection risks.
Cerus's top competitors include Aethlon Medical, PATH EX and Amferia.
Cerus offers INTERCEPT Blood System for Platelets and Plasma, INTERCEPT Blood System for Cryoprecipitation, and INTERCEPT Red Blood Cell System.
Yes, Cerus is publicly traded on NASDAQ under the ticker symbol CERS.
Cerus has 3 investors. Key investors include NCBI, MidCap Financial, and Military Health.
Cerus operates through Cerus Corporation.